
Yousef Zakharia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2145705/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 2019, 381, 338-348.	13.9	885
2	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 525-537.	5.1	225
3	Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Seminars in Immunopathology, 2019, 41, 41-48.	2.8	198
4	Mapping the immune environment in clear cell renal carcinoma by single-cell genomics. Communications Biology, 2021, 4, 122.	2.0	139
5	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncology, The, 2019, 20, 581-590.	5.1	124
6	Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. Frontiers in Oncology, 2018, 8, 370.	1.3	91
7	Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discovery, 2021, 11, 2998-3007.	7.7	80
8	Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. JAMA Oncology, 2020, 6, 1606.	3.4	79
9	Radioresistance in Glioblastoma and the Development of Radiosensitizers. Cancers, 2020, 12, 2511.	1.7	77
10	Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncology, The, 2022, 23, 248-258.	5.1	73
11	Impact of performance status on treatment outcomes: A realâ€world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer, 2020, 126, 1208-1216.	2.0	70
12	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). Journal of Clinical Oncology, 2020, 38, 4240-4248.	0.8	69
13	Advanced stage melanoma therapies: Detailing the present and exploring the future. Critical Reviews in Oncology/Hematology, 2019, 133, 99-111.	2.0	48
14	Obesity diminishes response to PD-1-based immunotherapies in renal cancer. , 2020, 8, e000725.		45
15	The effect of various vitamin D supplementation regimens in breast cancer patients. Breast Cancer Research and Treatment, 2011, 127, 171-177.	1.1	42
16	Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease. Journal of Investigative Medicine High Impact Case Reports, 2016, 4, 232470961667431.	0.3	40
17	Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncology, 2021, 7, 1815.	3.4	40
18	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. European Urology Oncology, 2021, 4, 464-472.	2.6	39

#	Article	IF	CITATIONS
19	Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma. , 2021, 9, e002057.		39
20	CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells. Nature Communications, 2021, 12, 5764.	5.8	38
21	The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma. Cancers, 2020, 12, 143.	1.7	36
22	Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma Journal of Clinical Oncology, 2018, 36, 9512-9512.	0.8	35
23	Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor TÂcell immunity. Immunity, 2021, 54, 2354-2371.e8.	6.6	34
24	Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study. Oncotarget, 2017, 8, 89182-89193.	0.8	33
25	Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). Cancer, 2021, 127, 2204-2212.	2.0	32
26	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. Journal of Urology, 2020, 204, 63-70.	0.2	32
27	Ipilimumab: from preclinical development to future clinical perspectives in melanoma. Future Oncology, 2017, 13, 625-636.	1.1	31
28	Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment. International Journal of Molecular Sciences, 2018, 19, 3834.	1.8	31
29	Understanding the Redox Biology of Selenium in the Search of Targeted Cancer Therapies. Antioxidants, 2020, 9, 420.	2.2	29
30	Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development. Oncotarget, 2018, 9, 10765-10783.	0.8	29
31	Ipilimumab-induced hypophysitis, a single academic center experience. Pituitary, 2019, 22, 488-496.	1.6	28
32	A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. Oncologist, 2020, 25, 121-e213.	1.9	28
33	Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer. Oncologist, 2020, 25, e1711-e1719.	1.9	28
34	Abstract CT117: Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma. Cancer Research, 2017, 77, CT117-CT117.	0.4	27
35	Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer, 2022, 128, 1194-1205.	2.0	26
36	Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review. Cancers, 2019, 11, 1950.	1.7	24

#	Article	IF	CITATIONS
37	Race and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trials. Future Oncology, 2021, 17, 3271-3280.	1.1	24
38	Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. Clinical Cancer Research, 2022, 28, 3248-3255.	3.2	24
39	Quantitative Test–Retest Measurement of ⁶⁸ Ga-PSMA-HBED-CC in Tumor and Normal Tissue. Journal of Nuclear Medicine, 2020, 61, 1145-1152.	2.8	23
40	Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. Annals of Translational Medicine, 2021, 9, 1033-1033.	0.7	23
41	Potential Role of Selenium in the Treatment of Cancer and Viral Infections. International Journal of Molecular Sciences, 2022, 23, 2215.	1.8	22
42	Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, e157-e166.	0.9	21
43	Current status of intralesional agents in treatment of malignant melanoma. Annals of Translational Medicine, 2021, 9, 1038-1038.	0.7	21
44	Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. , 2020, 8, e000538.		19
45	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU International, 2021, 128, 196-205.	1.3	18
46	Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer. Journal of Immunotherapy, 2018, 41, 42-44.	1.2	17
47	ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001 Journal of Clinical Oncology, 2020, 38, 5015-5015.	0.8	17
48	Qualityâ€ofâ€life outcomes in patients with advanced melanoma: A review of the literature. Pigment Cell and Melanoma Research, 2017, 30, 511-520.	1.5	16
49	Detection of pro angiogenic and inflammatory biomarkers in patients with CKD. Scientific Reports, 2021, 11, 8786.	1.6	16
50	Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events. Journal of Oncology, 2019, 2019, 1-7.	0.6	15
51	Immune checkpoint inhibitors in heart or lung transplantation: Early results from a registry initiative. Journal of Heart and Lung Transplantation, 2020, 39, 604-606.	0.3	15
52	Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Design, Development and Therapy, 2017, Volume11, 1175-1182.	2.0	14
53	Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma. Melanoma Research, 2019, 29, 643-647.	0.6	13
54	PARP Inhibitors in Prostate and Urothelial Cancers. Frontiers in Oncology, 2020, 10, 114.	1.3	13

#	Article	IF	CITATIONS
55	Breast Hormonal Receptors Test Should Be Repeated on Excisional Biopsy After Negative Core Needle Biopsy. Breast Journal, 2011, 17, 180-186.	0.4	12
56	Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies. Antibiotics, 2020, 9, 740.	1.5	11
57	Toxicities with targeted therapies after immunotherapy in metastatic melanoma. Melanoma Research, 2018, 28, 600-604.	0.6	10
58	Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces Together. Journal of Immunotherapy, 2018, 41, 359-360.	1.2	10
59	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, e440-e452.	0.9	10
60	Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma. Expert Opinion on Drug Discovery, 2015, 10, 925-935.	2.5	9
61	A phase 1b/2 study of the combination of the IDO pathway inhibitor indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors: Safety analysis and preliminary efficacy of the phase 1b component Journal of Clinical Oncology, 2015, 33, 2070-2070.	0.8	8
62	IMCT-21UPDATES ON PHASE 1B/2 COMBINATION STUDY OF THE IDO PATHWAY IHIBITOR INDOXIMOD WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS. Neuro-Oncology, 2015, 17, v112.2-v112.	0.6	7
63	Autoimmune retinopathy and optic neuropathy associated with enolase-positive renal oncocytoma. American Journal of Ophthalmology Case Reports, 2018, 12, 55-60.	0.4	7
64	Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy. Cancers, 2021, 13, 1489.	1.7	7
65	The clinical characteristics of melanoma with BRAF V600R mutation: a case series study. Melanoma Research, 2020, 30, 107-112.	0.6	6
66	Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). Oncologist, 2021, 26, 560-e1103.	1.9	6
67	Phase1 clinical trial of high doses of Seleno-L-methionine (SLM), in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients Journal of Clinical Oncology, 2018, 36, 630-630.	0.8	6
68	Immunotherapy Advances in Urothelial Carcinoma. Current Treatment Options in Oncology, 2018, 19, 79.	1.3	5
69	Computerized Decision Support for Bladder Cancer Treatment Response Assessment in CT Urography: Effect on Diagnostic Accuracy in Multi-Institution Multi-Specialty Study. Tomography, 2022, 8, 644-656.	0.8	5
70	HER2 Testing. Applied Immunohistochemistry and Molecular Morphology, 2011, 19, 424-430.	0.6	4
71	A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clinical Genitourinary Cancer, 2022, 20, 1-10.	0.9	4
72	Preliminary results of phase I clinical trial of high doses of seleno-L-methionine (SLM) in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients Journal of Clinical Oncology, 2019, 37, 660-660.	0.8	4

#	Article	IF	CITATIONS
73	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Clinical Genitourinary Cancer, 2022, 20, 165-175.	0.9	4
74	Ovarian Cancer from an Immune Perspective. Radiation Research, 2014, 182, 239-251.	0.7	3
75	Tumor Lysis Syndrome in a Retroperitoneal Sarcoma. Journal of Investigative Medicine High Impact Case Reports, 2014, 2, 232470961454234.	0.3	3
76	Association of prior local therapy and outcomes with programmedâ€death ligandâ€1 inhibitors in advanced urothelial cancer. BJU International, 2022, 130, 592-603.	1.3	3
77	Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology, 2022, 175, 103706.	2.0	3
78	Non–Muscle Invasive Papillary Urothelial Carcinoma Metastatic to the Mandible. Journal of Investigative Medicine High Impact Case Reports, 2018, 6, 232470961880633.	0.3	2
79	Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma. Case Reports in Oncological Medicine, 2019, 2019, 1-5.	0.2	1
80	Phase I with expansion clinical trial of seleno-l-methionine (SLM) in combination with axitinib in patients with relapsed clear cell renal cell carcinoma (ccRCC): Bench to bedside Journal of Clinical Oncology, 2021, 39, 322-322.	0.8	1
81	Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study. European Urology Focus, 2022, 8, 483-490.	1.6	1
82	Small bowel obstruction: a recurrence of melanoma during the second trimester of pregnancy. Proceedings in Obstetrics and Gynecology, 2017, 7, 1-7.	0.1	1
83	MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets. International Journal of Molecular Sciences, 2022, 23, 5604.	1.8	1